Viking Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, 157.85, 531.2, 1059.36 ], "ebit_estimate": [ -585.76, -615.03, -535.17, -272.68, 126.57 ], "ebitda_estimate": [ -618.12, -702.89, -581.07, -448.93, 39.1 ], "net_income_estimate": [ -563.91, -592.95, -522.15, -254.42, 341.89 ], "per_share_eps_estimate": [ -4.78, -4.76, -3.95, -1.88, 2.37 ], "eps_nri_estimate": [ -4.8, -4.77, -4.05, -1.04, 2.16 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 3.58, 5.92, 1.46, null, null ], "pretax_income_estimate": [ -558.85, -591.16, -501.67, -240.4, 390.18 ], "operating_cash_flow_per_share_estimate": [ -4.51, -3.7, null, null, null ], "roa_estimate": [ -130.5, -79.3, null, null, null ], "roe_estimate": [ -116.45, -97.29, -156.16, null, null ], "gross_margin_estimate": [ null, null, 82, 84, 85 ], "operating_cash_flow_estimate": [ -521.21, -427.6, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 16.41 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": -13.91, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -12.4, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -29.61, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -40.51, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ null, null, null, null, null, null, null, null ], "ebit_estimate": [ -150.31, -137.98, -134.46, -140.47, -142.17, -144.06, -146.19, null ], "ebitda_estimate": [ -158.82, -154.29, -160.74, null, null, null, null, null ], "net_income_estimate": [ -144.71, -130.61, -126.65, -133.34, -135.38, -137.84, -138.63, null ], "per_share_eps_estimate": [ -1.25, -1.1, -1.06, -0.96, -0.94, -0.93, -0.92, null ], "eps_nri_estimate": [ -1.25, -1.12, -1.08, -0.96, -0.94, -0.93, -0.92, -0.73 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 3.97, 3.33, 2.66, null, null, null, null, null ], "pretax_income_estimate": [ -143.65, -128.96, -124.18, -133.34, -135.38, -137.84, -138.63, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": -13.91, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -12.4, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -29.61, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -40.51, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }